Prof. Mert BAŞARAN

Publication Network

Articles 49

1. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

Yildirim H. C., BAYRAM E., Chalabiyev E., Majidova N., Avci T., Güzel H. G., et al.

Journal of Chemotherapy , vol.37, no.6, pp.551-562, 2025 (SCI-Expanded)

2. Perceptions and Expectations: A Study on Prognostic Perception and Quality of Life in Patients With Metastatic Renal and Bladder Cancer

BÖLEK H., Arslan C., BAŞARAN M., ÇİÇİN İ., ÖZGÜROĞLU M., Tural D., et al.

JCO Global Oncology , vol.10, 2024 (ESCI)

3. Therapeutic efficacy of high-dose chemotherapy with autologous stem-cell transplantation in 44 relapsed or refractory germ-cell tumor patients: A retrospective cohort study

Ferhatoglu F., Paksoy N., Khanmammadov N., YILDIZ A., AHMED M. A., Gülbas Z., et al.

Medicine , vol.103, no.8, 2024 (SCI-Expanded) Sustainable Development

4. Efficacy and safety of sorafenib in adult metastatic osteosarcoma patients

Dogan I., PAKSOY N., BAŞARAN M.

Journal of Cancer Research and Therapeutics , vol.20, no.3, pp.979-983, 2024 (SCI-Expanded)

5. Single-agent temozolomide as salvage therapy in heavily pretreated metastatic sarcoma patients

Dogan I., Paksoy N., BAŞARAN M.

Journal of Cancer Research and Therapeutics , vol.20, no.1, pp.93-97, 2024 (SCI-Expanded)

6. Cisplatin-docetaxel induction chemotherapy for patients with nasopharyngeal carcinoma in a non-endemic cohort

ÖZKAYA TORAMAN K., MERAL R., Karadeniz A. N., Kaval G., BAŞARAN M., EKENEL M., et al.

Journal of Chemotherapy , vol.36, no.2, pp.133-142, 2024 (SCI-Expanded)

7. Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience

Pehlivan M., Paksoy N., Aydin E., BAŞARAN M., EKENEL M.

Medicine , vol.102, no.41, 2023 (SCI-Expanded) Sustainable Development

8. Clinical course and features of soft tissue sarcomas in geriatric patients: a single-center experience

Pehlivan M., İribaş A., Bilgiç B., BAŞARAN M., EKENEL M.

Journal of International Medical Research , vol.51, no.3, 2023 (SCI-Expanded)

9. Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma

DOĞAN İ., Iribas A., Ahmed M. A., Basaran M.

JOURNAL OF CHEMOTHERAPY , vol.35, no.4, pp.343-347, 2023 (SCI-Expanded)

10. High-dose chemotherapy followed by autologous stem cell transplantation for adult patients with first relapse of Ewing's sarcoma: A single institution experience

PAKSOY N., FERHATOĞLU F., DOĞAN İ., KHANMAMMADOV N., Iribas Celik A., Gulbas Z., et al.

Medicine (United States) , vol.101, no.49, 2022 (SCI-Expanded)

11. Multidrug refractory aggressive metastatic TFE3 (+) renal cell carcinoma: A case report.

Paksoy N., Erdem S., Karaca M., Ak N., Pehlivan M., Yirgin İ., et al.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners , vol.28, no.1, pp.215-221, 2022 (SCI-Expanded)

12. Efficacy of vincristine, irinotecan, and temozolomide (VIT) combination in adult patients with metastatic Ewing sarcoma.

Dogan I., Iribas A., Ekenel M., Basaran M.

JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021 (SCI-Expanded)

13. Efficacy of temozolomide in pretreated patients with metastatic sarcoma.

Paksoy N., Dogan I., Ekenel M., Basaran M.

JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021 (SCI-Expanded)

14. Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors.

Ferhatoglu F., Paksoy N., Dogan I., Ak N., Pehlivan M., Ekenel M., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021 (SCI-Expanded)

15. Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma.

Paksoy N., Dogan I., Ekenel M., Basaran M.

JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021 (SCI-Expanded)

16. Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases.

Dogan I., Iribas A., Paksoy N., Ekenel M., Vatansever S., Basaran M.

JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6, 2021 (SCI-Expanded)

17. Y⁹⁰ selective internal radiation therapy and peptide receptor radionuclide therapy for the treatment of metastatic neuroendocrine tumors: combination or not?

Yilmaz E., Engin M. N., Oezkan Z. G., Kovan B., Bueyuekkaya F., Poyanli A., et al.

NUCLEAR MEDICINE COMMUNICATIONS , no.12, pp.1242-1249, 2020 (SCI-Expanded, Scopus) Sustainable Development

18. Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy

YILDIZ İ., Bilici A., Karadurmus N., Ozer L., Tural D., Kaplan M. A., et al.

TUMORI J , vol.104, no.6, pp.444-450, 2018 (SCI-Expanded)

19. Middle East observational study in metastatic soft tissue sarcoma: an epidemiological study on the treatment patterns (MOON)

Memon M. A., Karaca B., Aboelhassan R., Barsoum M., ERMAN M., BAŞARAN M., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.144, no.11, pp.2219-2229, 2018 (SCI-Expanded)

20. 22-year survival following radical nephrectomy and several metastasectomies in a case of renal cell carcinoma

Yucel O. B., Tunc H. M., Basaran M., Aras N.

TURKISH JOURNAL OF UROLOGY , vol.43, no.2, pp.216-219, 2017 (ESCI)

21. Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials

Bono P., Oudard S., Bodrogi I., Hutson T. E., Escudier B., Machiels J., et al.

CLINICAL GENITOURINARY CANCER , vol.14, no.5, pp.406-414, 2016 (SCI-Expanded) Sustainable Development

22. Renal cell cancer: overview of the current therapeutic landscape

ERMAN M., BENEKLİ M., Basaran M., Bavbek S., Buyukberber S., Coskun U., et al.

EXPERT REVIEW OF ANTICANCER THERAPY , vol.16, no.9, pp.955-968, 2016 (SCI-Expanded) Sustainable Development

23. The Prognostic Factors and Outcome of Adult Medulloblastoma: Where We Stand

Ibis K., Karadeniz A., Meral R., Guveli M., Basaran M., Bavbek S., et al.

INTERNATIONAL SURGERY , vol.101, pp.352-360, 2016 (SCI-Expanded, Scopus)

24. HEMATOLOGIC PARAMETERS IN GERIATRIC PATIENTS WITH IDIOPATHIC SUDDEN SENSORINEURAL HEARING LOSS

Ezerarslan H., BAŞARAN M.

TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI , vol.19, no.1, pp.35-41, 2016 (SCI-Expanded)

25. Sunitinib ile tedavi edilen metastatik böbrek hücreli karsinom hastalarının klinik olarak değerlendirilmesi: Tek merkez deneyimi

KARABULUT S., EKENEL M., IRIBAS A., DARENDELILER E., BAŞARAN M., BAVBEK S. E.

TÜRK ONKOLOJİ DERGİSİ , vol.30, pp.51-60, 2015 (Scopus)

26. Clinical evaluation of sunitinib in patients with metastatic renal cell carcinoma: Single center experience

Karabulut S., Ekenel M., Iribas A., Darendeliler E., Basaran M., Bevbek S.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.30, no.2, pp.51-60, 2015 (ESCI)

27. Fourth versus eighth week surgery after neoadjuvant radiochemotherapy in T3-4/N0+ rectal cancer: Istanbul R-01 study

Saglam S., Bugra D., KAYTAN SAĞLAM E., Asoglu O., Balik E., Yamaner S., et al.

JOURNAL OF GASTROINTESTINAL ONCOLOGY , vol.5, no.1, pp.9-17, 2014 (ESCI) Sustainable Development

28. A case of non-Hodgkin lymphoma coexisting with both hepatitis B and tuberculosis

Yildiz I., Varol U., Varol Y., BAŞARAN M.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.29, no.2, pp.53-56, 2014 (ESCI) Sustainable Development

29. Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma

Yildiz I., Sen F., Kilic L., Ciftci R., BAŞARAN M.

KOREAN JOURNAL OF UROLOGY , vol.55, no.1, pp.74-76, 2014 (ESCI)

30. Successful treatment of triple primary tumor

Kurul S., Akgun Z., DAĞOĞLU SAKİN R. N., BAŞARAN M., Yucel S., Tuzlali S.

INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS , vol.4, no.11, pp.1013-1016, 2013 (ESCI)

31. Primary Burkitt's Lymphoma Presenting as a Rapidly Growing Thyroid Mass

Yildiz I., Sen F., Toz B., Kilic L., Agan M., BAŞARAN M.

CASE REPORTS IN ONCOLOGY , vol.5, no.2, pp.388-393, 2012 (ESCI)

32. Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey

Yildiz I., Sen F., Basaran M., Ekenel M., Agaoglu F., Darendeliler E., et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.12, pp.1380-1387, 2011 (SCI-Expanded)

33. Optic Disc and Choroidal Metastasis from Sporadic Medullary Thyroid Carcinoma: Case Report and Review of the Literature

Yildiz I., Sen F., Tuncer S., Kilic L., Basaran M., BAVBEK S.

ONKOLOGIE , vol.34, no.11, pp.630-633, 2011 (SCI-Expanded) Sustainable Development

34. Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Alone in Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma: Do We Really Have Robust Data?

Basaran G., Agaoglu F., Basaran M.

JOURNAL OF CLINICAL ONCOLOGY , vol.28, no.27, 2010 (SCI-Expanded)

35. Primary mucosal malignant melanoma of the nasopharynx: two case reports

Karadeniz A., Gurocak S., Biliciler N., BAŞARAN M., TAŞ F.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.24, no.3, pp.131-137, 2009 (ESCI)

36. Serum Levels of Interleukin-6 and Interleukin-10 in Turkish Patients with Aggressive Non-Hodgkin's Lymphoma

Güney N., Soydinc H. O., Basaran M., BAVBEK S., Derin D., Camlica H., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.10, no.4, pp.669-674, 2009 (SCI-Expanded, Scopus)

37. Clinical outcome of rhabdomyosarcoma in adolescent and adult patients: Single center experience from Turkey

Ustuner Z., Basaran M., Dizdar Y., Agaoglu F. Y., Bilgic B., Sakar B., et al.

TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE , vol.213, no.3, pp.221-229, 2007 (SCI-Expanded) Sustainable Development

38. Pituitary apoplexy following coronary artery bypass grafting

Ugurlucan M., Yerebakan C., BAŞARAN M., Sever K., TANSEL T., Dayioglu E., et al.

ZEITSCHRIFT FUR HERZ THORAX UND GEFASSCHIRURGIE , vol.21, no.5, pp.217-220, 2007 (ESCI)

39. Acute anterior myocardial infarction after chemotherapy for testicular seminoma in a young patient

Ozben B., Kurt R., Oflaz H., Sezer M., Basaran M., Goren T., et al.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , vol.13, no.4, pp.439-442, 2007 (SCI-Expanded) Sustainable Development

40. A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas

Basaran M., Bavbek E. S., Saglam S., Eralp L., Sakar B., Atalar A. C., et al.

ONCOLOGY , vol.72, pp.255-260, 2007 (SCI-Expanded)

41. Primary non-Hodgkin's lymphoma of the rectum

Guney N., Basaran M., Aksakalli N., Bavbek S., Erseven G.

ONKOLOGIE , vol.30, pp.385-387, 2007 (SCI-Expanded)

42. Malignant mesothelioma of the tunica vaginalis testis: a case report and review of the literature

Guney N., Basaran M., Karayigit E., Muesluemanoglu A., Guney S., Kilicaslan I., et al.

MEDICAL ONCOLOGY , vol.24, no.4, pp.449-452, 2007 (SCI-Expanded)

43. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma without complete response to first-line therapy

Alici S., Bavbek S., Basaran M., Onat H.

ADVANCES IN THERAPY , vol.23, no.4, pp.534-542, 2006 (SCI-Expanded)

44. ANTIEMETIC EFFICACY OF DIAZEPAM IN THE PROPHYLAXIS OF ACUTE AND DELAYED EMESIS INDUCED BY CISPLATIN BASED CHEMOTHERAPY TREATED WITH STANDARD ANTI EMETICS

SAİP P. M., Onat H., Uygun K., Demir C., Salepci T., Guney N., et al.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.20, no.2, pp.67-72, 2005 (ESCI)

45. The vascular manifestations of Behçet's disease: A case report Les manifestations vasculaires de la maladie de Behçet: À propos d'un cas

BAŞARAN M., SEVER K., KAFALI E., Ugurlucan M., ALPAGUT U., DAYIOGLU E.

Annales de Cardiologie et d'Angeiologie , vol.54, no.2, pp.86-88, 2005 (SCI-Expanded)

46. Ewing's sarcoma of the axial system in patients older than 15 years: Dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment

Argon A., Basaran M., Yaman F., Dizdar Y., Sakar B., Camlica H., et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY , vol.34, no.11, pp.667-672, 2004 (SCI-Expanded)

47. Clinicopathologic factors influencing survival of patients with bile duct and gallbladder carcinoma

Sakar B., Basaran M., Gumus M., Yazar A., Argon A., Aykan N. F.

ANNALS OF ONCOLOGY , vol.15, pp.243-244, 2004 (SCI-Expanded)

48. OSTEOSARKOMLU HASTALARDA METHOTREXATE DÜZEYLERİNİN DEĞERLENDİRİLMESİ

Kaya S., ŞENTÜRK ÇİFTÇİ H., Kılıçarslan Ayna T., Görgün Ö., BAŞARAN M., GÜRTEKİN M., et al.

Journal of Istanbul Faculty Medicine , no.64, pp.59-65, 2001 (Peer-Reviewed Journal)

49. Long term results and prognostic factors of granulosa cell tumors of the ovary.

SAİP P. M., Uygun K., Topuz E., BAŞARAN M., TAŞ F., AYDINER A., et al.

ANNALS OF ONCOLOGY , vol.11, pp.87, 2000 (SCI-Expanded)

Papers Presented at Peer-Reviewed Scientific Conferences 56

1. GENİŞLETİLMİŞ 177LU-PSMA TEDAVİSİ UYGULANAN HASTALARDA ABSORBE BÖBREK DOZU CKD-EPİ DEĞERLERİNİ NASIL ETKİLİYOR?

, Topal E., Kovan B., İribaş Çelik A., Kuyumcu S., Başaran M., et al.

36. Ulusal Nükleer Tıp Kongresi, Girne, Cyprus (Kktc), 8 - 12 May 2024, pp.11, (Summary Text)

2. The efficacy of prognostic factors derived from Ga68-PSMA PET-CT images in predicting treatment response and survival in patients with metastatic castration-resistant prostate cancer treated with Lu-177PSMA

Oflas M., Has Şimşek D., Şanlı Y., Kuyumcu S., Işık E. G., Karadoğan S., et al.

EANM’23, Vienna, Austria, 9 - 13 September 2023, (Full Text) Sustainable Development

3. Evaluation of Nephrotoxicity of Extended Lu177-PSMA in Patients with Metastatic Castration-Resistant Prostate Cancer

Topal E., Kovan B., Has Şimşek D., Şanlı M. Ö., Başaran M., Şanlı Y.

European Association of Nuclear Medicine Congress, Vienna, Austria, 9 - 13 September 2023, pp.151-152, (Summary Text)

4. Safety and survival in adult women with platinum sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program-LynTurk study

Esin E., Ahmed M. A., Yildirim H. C., Mandel N. M., Erdemoglu E., SARI M., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 06 June 2023, (Summary Text)

5.

Topal E., Kovan B., Has Şimşek D., Civan C., Şanlı M. Ö., Başaran M., et al.

Uluslararasi Uroloji Arastirmalari Dernegi Kongresi (IURES), İstanbul, Turkey, 18 - 20 May 2023, pp.1, (Summary Text)

6. LU177-PSMA TEDAVİSİ VERİLEN PROSTAT KANSERLİ HASTALARDA GA-68 PET/BT İLE TEDAVİ YANITI VE PROGNOSTİK DEĞERLENDİRME

Oflas M., Has Şimşek D., Şanlı Y., Kuyumcu S., Işık E. G., Karadoğan S., et al.

35. Ulusal Nükleer Tıp Kongresi, Antalya, Turkey, 26 - 30 April 2023, (Summary Text) Sustainable Development

7. MKDPK Tanılı Hastalarda Lu-177-PSMA ve 2. Jenerasyon Antiandrojen Kombine Tedavisinin Sağkalım Üzerine Etkisi

Kıran M. Y., Has Şimşek D., Civan C., Başaran M., Şanlı Y.

34. ULUSAL NÜKLEER TIP KONGRESİ, Antalya, Turkey, 27 - 31 March 2022, pp.16, (Summary Text)

8. Metastasis Of Medullary Thyroid Carcinoma Detected With 68GA-FAPİ-04 PET/CT

Rasulova N., Işık E. G., Başaran M., Gül N., Kubat Üzüm A., Soyluk Selçukbiricik Ö.

Endobridge 2021, 21 - 24 October 2021, pp.3, (Summary Text)

9. Metastatik kastrasyona dirençli prostat kanserinde Ac-225 PSMA tedavisi: İlk sonuçlarımız

Şanlı Y., Has Şimşek D., Işık E. G., Civan C., Başaran M., Özkan Z. G., et al.

33. Ulusal Nükleer Tıp Kongresi, 28 May 2021, pp.32, (Summary Text) Sustainable Development

10. Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma(NPC) patients treated between 2004 and 2016: Patient and treatment characteristics and long term outcome.

Altun M., Kaval G., Ibis K., Ozkaya K., Meral R., Karadeniz A. N., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37, (Summary Text)

11. Nazofarenks kanserinde indüksiyon kemoterapi ve eşzamanlı kemoradyoterapi. , 17-21 Nisan 2019, Antalya.

ALTUN M., KAVAL G., İBİŞ K., ÖZKAYA TORAMAN K., MERAL R., KARADENİZ A. N., et al.

23. Ulusal Kanser Kongresi, Antalya, Turkey, 17 - 21 April 2019, (Full Text)

12. Nazofarenks kanserinde yaş gruplarına göre hastalık kontrolü ve sağkalım. 17-21 Nisan 2019, Antalya.

İBİŞ K., KAVAL G., MERAL R., KARADENİZ A. N., ÖZKAYA TORAMAN K., KEBUDİ R., et al.

23. Ulusal Kanser Kongresi, Turkey, 17 - 21 April 2019, (Full Text)

13. Sağ atriyumu invaze eden seviye 4 kava trombüslü bir böbrek tümörünün multidisipliner cerrahi tedavisi (sunulu video)

ERDEM S., ÖZCAN F., ANDER A. H., GASİMOV K., UĞURLUCAN M., SAYIN Ö. A., et al.

26. Ulusal Üroloji Kongresi, Girne, Cyprus (Kktc), 12 - 15 October 2017, (Full Text)

14. Evre IE serviks lenfoması

İBİŞ K., KÜÇÜCÜK N. S., BAŞARAN M., ENGİN G., ŞANLI Y., YAVUZ E., et al.

22. Ulusal Kanser Kongresi, Turkey, 19 - 23 April 2017, (Summary Text)

15. Erişkin medulloblastomada tedavi deneyim

İBİŞ K., KARADENİZ A. N., MERAL R., güveli m., BAŞARAN M., BAVBEK S., et al.

11. Ulusal Radyasyon Onkolojisi Kongresi, Turkey, 23 - 26 April 2014, (Summary Text)

16. Metastatik hormona dirençli prostat kanserinde abirateron deneyimiz

KARABULUT S., EKENEL M., ÇİFTÇİ R., ÇELEBİ K., İRİBAŞ A., DARENDELİLER M. E., et al.

Avrasya Üronkoloji Bahar Kongresi, Bursa, Turkey, 28 April - 01 May 2016 Sustainable Development

17. Olgu bildirimi: Nüks düşük gradlı glial tümörde bevasizumab sonrası wallerian dejenerasyon

KILIÇ L., EKENEL M., YILDIZ I., ŞEN F., ÇİFTÇİ R., BAŞARAN M., et al.

6. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 23 - 27 March 2016, pp.346, (Full Text)

18. Do serum nectin-2 levels have a prognostic effect in patients with colorectal cancer?

Basaran M., KARABULUT S., KARABULUT M., GUNALDI M., ALIS H., Erturk K., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33, (Summary Text) Sustainable Development

19. Opere yumuşak doku sarkomlu hastalarda postoperatif radyoterapi sonuçları

IRIBAS A., ÖZKURT S., AĞAOĞLU F., BAŞARAN M., ÖZGER H., ERALP L., et al.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.517, (Full Text)

20. Sunitinib ile tedavi edilen metastatik renal hücreli karsinom (MRHK)hasta sonuçları, tek merkez deneyimi

EKENEL M., KARABULUT S., YILDIZ İ., IRIBAS A., DARENDELİLER E., BAŞARAN M., et al.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.256, (Full Text)

21. Yüksek vücut kitle indeksi (VKİ)hedefe yönelik tedavi alan metastatik renal hücreli karsinom (BHK) hastalarında daha iyi sağkalımı öngörüyor mu?

KARABULUT S., EKENEL M., YILDIZ I., IRIBAS A., DARENDELİLER E., BAŞARAN M., et al.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.552, (Full Text)

22. Metastatik kastrasyona dirençli prostat kanserinde abireteron deneyimimiz

EKENEL M., ÇİFTÇİ R., KARABULUT S., ÇELEBİ K., IRIBAS A., DARENDELİLER E., et al.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.552, (Full Text) Sustainable Development

23. Metastatik böbrek hücreli tümörlerde sunitinib sonrası everolimus etkinliği

EKENEL M., KARABULUT S., IRIBAS A., DARENDELİLER E., BAVBEK S., BAŞARAN M.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.553, (Full Text)

24. Trombozu olan metastatik böbrek hücreli tümörlerde sunitinib tedavisinin sonuçları

EKENEL M., KARABULUT S., IRIBAS A., DARENDELİLER E., BAVBEK S., BAŞARAN M.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.552, (Full Text)

25. Sunitinib in patients with metastatic non-clear renal cell carcinoma: A multicentric retpospective Turkish Oncology Group (TOG) trial.

Yildiz I., Ekenel M., Altman T., KOCAR M., Uysal M., Kanitez M., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32, (Summary Text)

26. Systemic ritoximab immunotherapy in the management of primary ocular adoexal lymphoma: Slagle institution experience.

Tuncer S., Basaran M., Tanyildiz B., Buyukbabani N., Basaran G., Dogan O.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32, (Summary Text)

27. Metastatik berrak hücreli dışı kanserde sunitinib tedavisinin etkinliği ve tosisitesi: Çok merkezli retrospektif TOG çalışması

YILDIZ İ., EKENEL M., AKMAN T., KOCAR M., UYSAL M., KANITEZ M., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.326-327, (Full Text) Sustainable Development

28. Nüks ya da primer refrakter ewing sarkomlu hastalarda sağkalım ve genel sağkalımla ilişkili prognostik faktörler: 13 yıllık tek merkez deneyimi

YILDIZ İ., ŞEN F., EKENEL M., DARENDELİLER E., AĞAOĞLU F., BAVBEK S., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.321, (Full Text)

29. ANTİ-VEGF TKİ VERİLEN BEYİN METASTAZLI RENAL HÜCRELİ KANSER OLGULARINDA KLİNİK SONUÇLAR VE PROGNOSTİK FAKTÖRLER: ÇOK MERKEZLİ TOG ÇALIŞMASI İLK SONUÇLARI

YILDIZ I., EKENEL M., AKMAN T., BAYOGLU I. V., TURAL D., YAZICI O., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.549, (Full Text) Sustainable Development

30. Platin dirençli nüks eden baş boyun tümörlerinde setuximabın rolü, olgu değerlendirmesi

Karabulut S., Ekenel M., Tambaş M., Taştekin D., Altun M., Meral R., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.363, (Full Text)

31. Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).

Malik Z., di Lorenzo G., Bracarda S., Ardavanis A., Basaran M., Parente P., et al.

Genitourinary Cancers Symposium, San-Francisco, Costa Rica, 30 January - 01 February 2014, vol.32, (Summary Text) Sustainable Development

32. Cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): Analysis by age group

Malik Z., di Lorenzo G., Bracarda S., Ardavanis A., Basaran M., Parente P., et al.

Genitourinary Cancers Symposium, San-Francisco, Costa Rica, 30 January - 01 February 2014, vol.32, (Summary Text) Sustainable Development

33. Interim safety analysis of a compassionate-use program (CUP) and early-access program (EAP) providing cabazitaxel (Cbz) plus prednisone (P) to patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel

Malik Z. I., Di Lorenzo G., Basaran M., Ardavanis A., Parente P., de Schultz W., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31, (Summary Text) Sustainable Development

34. Is there any prognostic importance of pretreatment serum M30 and serum M65 levels on progression-free survival of patients with metastatic renal cell carcinoma treated with first-line sunitinib?

Basaran M., Yildiz I., Sen F., Kilic L., Keskin S., Darendeliler E., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31, (Summary Text)

35. Mesane kanseri tanılı hastalarda organ koruyucu tedavi sonuçlarımız

IRIBAS A., AĞAOĞLU F., ÖZKURT S., KILIC L., EKENEL M., BAŞARAN M., et al.

20. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2013, pp.173, (Full Text) Sustainable Development

36. Rezektabl desmoid tümörlerde pozitif cerrahi sınırın ve postoperatif radyoterapinin klinik önemi

KARABULUT S., KESKİN S., EKENEL M., ÇİFTÇİ R., BAŞARAN M., AĞAOĞLU F., et al.

20. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2013, pp.274, (Full Text)

37. Sunitinib ile tedavi edilen metastatik kanserli hastalarda koroner akım rezervinin değerlendirilmesi

SEN F., YILDIZ I., BAŞARAN M., EKENEL M., KILIÇ L., ÖZ F., et al.

4. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2012, pp.294, (Full Text) Sustainable Development

38. Metastatik böbrek hücreli kanserde sunitinib tedavisi altındaki hastalarda prognostik faktörler

YILDIZ İ., ŞEN F., BAŞARAN M., EKENEL M., KILIC L., BAVBEK S.

4. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2012, pp.123, (Full Text) Sustainable Development

39. Olgu bildirimi: Tekrarlayan düşük gradlı glial tümörde bevasizumab ve irinotekanla tam yanıt

KILIC L., EKENEL M., YILDIZ İ., ŞEN F., KESKİN S., AYDOGAN F., et al.

4. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2012, pp.161, (Full Text)

40. Olgu bildirimi: 17 yıl sonra nüks eden bir testis tümörü olgusu, malign germ hücreli tümörlerde geç nükslerin önemi

KILIC L., SEN F., YILDIZ İ., KESKİN S., EKENEL M., BAŞARAN M.

4. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2012, pp.202, (Full Text)

41. Olgu bildirimi: Desmoplastik küçük yuvarlak hücreli tümör, uzun süreli sağkalım mümkün mü?

KILIC L., EKENEL M., ŞEN F., YILDIZ İ., KESKİN S., AYDOGAN F., et al.

4. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2012, pp.180, (Full Text)

42. Türk toplumunda metastatik böbrek kanserinde kesintisiz, günde tek doz olarak verilen sunitinib tedavisinin toksisitesi

BAŞARAN M., YILDIZ I., ŞEN F., EKENEL M., BAVBEK S.

4. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2012, pp.110, (Full Text) Sustainable Development

43. Predictive significance of marker half life during chemotherapy in relapsed and non relapsed patients with non seminomatous germ cell testicular tumors

KESKİN S., EKENEL M., KARABULUT S., BAŞARAN M., BAVBEK S.

2nd Mediterranean Multidisciplinary Oncology Forum, İstanbul, Turkey, 17 - 19 November 2011, (Full Text)

44. Non Hodgkin Lenfoma Tanılı Hastada F 18 FDG PET BT de Bilateral Böbrek ve Üreter Tutulumu

YILMAZ E., KADIOĞLU N., KUYUMCU S., ŞANLI Y., ÖZKAN Z. G., BAŞARAN M., et al.

4. PET-BT Sempozyumu, Turkey, 18 - 20 November 2011, pp.40-41

45. Pirimer veya nüks lokal ileri baş boyun kanserli hastaların tedavisinde eş zamanlı setuksimab/radyoterapi: Tek merkez deneyimi

ŞEN F., YILDIZ İ., ÖZDEMİR C., ALTUN M., BAŞARAN M., BAVBEK S.

XIX. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2011, pp.40, (Full Text) Sustainable Development

46. Clinical outcomes in patients with locally advanced nasopharyngeal cancer treated with neoadjuvant docetaxel and cisplatin followed by radiation treatment and concomitant cisplatin

Ekenel M., Keskin S., Başaran M., Bavbek S., Özdemir C., Meral R., et al.

American Society of Clinical Oncology (ASCO®) 2010 Annual Meeting, Illinois, United States Of America, 4 - 08 June 2010, vol.28, pp.16017, (Summary Text) Sustainable Development

47. Lokal ileri nazofarenks karsinomalı hastalarda neoadjuvan dosetaksel ve cisplatin sonrası kemoradyoterapi sonuçlarımız

EKENEL M., KESKİN S., BAŞARAN M., BAVBEK S., ÖZDEMİR C., MERAL R., et al.

III. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 24 - 28 March 2010, pp.23, (Full Text)

48. Evre I nonseminnmatöz testis kanserlerinde tedavisiz izlem sonuçlarımız

KESKİN S., EKENEL M., BAŞARAN M., BAVBEK S., ESEN T., ÖZCAN F., et al.

III. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 24 - 28 March 2010, pp.6, (Full Text) Sustainable Development

49. Nonseminomatöz germ hücreli testis tümörlerinde markır yarı ömrünün nüks eden ve etmeyen hasta gruplarında değerlendirilmesi

KESKİN S., EKENEL M., BAŞARAN M., BAVBEK S.

III. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 24 - 28 March 2010, pp.7, (Full Text)

50. Nefroblastom komponenti içeren testiküler teratom, literatürdeki ilk vaka

KESKİN S., EKENEL M., BAŞARAN M., BAVBEK S.

III. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 24 - 28 March 2010, pp.126, (Full Text)

51. Paratestiküler rabdomyosarkomlu sekiz vakanın değerlendirilmesi

KESKİN S., EKENEL M., BAŞARAN M., BAVBEK S.

III. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 24 - 28 March 2010, pp.123, (Full Text)

52. Non Hodgkin Lenfomalı Hastalarda Serum IL-2R Değerleri

OĞUZ SOYDİNÇ H., DURANYILDIZ D., GUNEY N., CAMLICA H., BAŞARAN M., YASASEVER V.

XVIII. Ulusal Kanser Kongresi, Antalya, Turkey, 21 - 26 April 2009, pp.1, (Full Text)

53. Von Hippel Lİndau Ailesinin Genetik Açıdan İncelenmesi

IŞIN M., Beşer A. R., BAŞARAN M., DALAY M. N.

XVII. Ulusal Kanser Kongresi, Antalya, Antalya, Turkey, 19 - 21 April 2007, pp.23-203, (Full Text)

54. Feasibility of close surveillance in stage/nonseminomatous testicular germ cell cancer: Single institution experience

Bavbek E. S., Derin D., Ozturk B., BAŞARAN M., Onat H.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.157, (Summary Text)

55. A single institution experience: Paclitaxel/ifosfamide/cisplatin (TIP) chemotherapy in refractory or recurrent germ cell tumors.

Karagol H., Derin D., Yazar A., BAŞARAN M., Bavbek S., Onat H.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22, (Summary Text)

56. Osteosarkomlu Hastalarda Methotrexate Düzeylerinin Değerlendirilmesi.

Aygün Kaya S., ŞENTÜRK ÇİFTÇİ H., Kılıçarslan Ayna T., Görgün Ö., BAŞARAN M., GÜRTEKİN M., et al.

6. Ulusal Tıbbi Biyoloji Kongresi, Denizli, Turkey, 2 - 05 November 1998, pp.171, (Full Text)

Metrics

Publication

105

Publication (WoS)

Publication (Scopus)

Citation (WoS)

197

H-Index (WoS)

Citation (Scopus)

208

H-Index (Scopus)

Citation (Scholar)

H-Index (Scholar)

Project

UN Sustainable Development Goals

Publications & Works

Publication

Publication (WoS)

Publication (Scopus)

Citation (WoS)

H-Index (WoS)

Citation (Scopus)

H-Index (Scopus)

Citation (Scholar)

H-Index (Scholar)

Project